Recent Investment Analysts’ Ratings Changes for Pharvaris (PHVS)

A number of research firms have changed their ratings and price targets for Pharvaris (NASDAQ: PHVS):

• 4/15/2026 – Pharvaris had its “buy” rating reaffirmed by Citigroup Inc..
• 4/13/2026 – Pharvaris was downgraded by Wall Street Zen from “sell” to “strong sell”.
• 4/9/2026 – Pharvaris is now covered by Wolfe Research. They set an “outperform” rating and a $42.00 price target on the stock.
• 4/8/2026 – Pharvaris is now covered by Wolfe Research. They set an “outperform” rating and a $42.00 price target on the stock.
• 4/7/2026 – Pharvaris had its price target raised by Wedbush from $41.00 to $42.00. They now have an “outperform” rating on the stock.
• 4/6/2026 – Pharvaris had its price target lowered by Royal Bank Of Canada from $52.00 to $51.00. They now have an “outperform” rating on the stock.
• 4/5/2026 – Pharvaris was downgraded by Wall Street Zen from “hold” to “sell”.
• 3/28/2026 – Pharvaris was upgraded by Wall Street Zen from “sell” to “hold”.
• 3/9/2026 – Pharvaris is now covered by Royal Bank Of Canada. They set an “outperform” rating and a $52.00 price target on the stock.
• 3/3/2026 – Pharvaris had its “buy” rating reaffirmed by HC Wainwright. They now have a $60.00 price target on the stock.
• 2/28/2026 – Pharvaris was downgraded by Wall Street Zen from “hold” to “sell”.

Insider Buying and Selling

In other Pharvaris news, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of $28.60, for a total transaction of $65,551.20. Following the completion of the sale, the chief executive officer owned 139,792 shares in the company, valued at approximately $3,998,051.20. The trade was a 1.61% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.